Drugs Made In America Acquisition Corp 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number:001-42467 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ☐Large accelerated filer☒Non-accelerated filer ☐Accelerated filer☒Smaller reporting company☒Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☒No☐ As of May 14, 2026, there were 24,276,913 ordinary shares outstanding (inclusive of shares included in outstanding units). DRUGS MADE IN AMERICA ACQUISITION CORP. TABLE OF CONTENTS PagePart I – Financial InformationItem 1. Financial Statements1Balance Sheets as of March 31, 2026 and December 31, 2025 (Unaudited)1Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (Unaudited)2Statements of Changes in Shareholders’ Deficit for the Three Months Ended March 31, 2026 and 2025 (Unaudited)3Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)4Notes to the Unaudited Financial Statements5Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3. Quantitative and Qualitative Disclosures About Market Risk24Item 4. Controls and Procedures24Part II – Other InformationItem 1. Legal Proceedings25Item 1A. Risk Factors25Item 2. Unregistered Sales of Equity Securities and Use of Proceeds25Item 3. Defaults Upon Senior Securities25Item 4. Mine Safety Disclosures25Item 5. Other Information25Item 6. Exhibits26Signatures27 PART I – FINANCIAL INFORMATION LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION ANDSHAREHOLDERS’ DEFICITCurrent liabilities Accounts payable and accrued expenses$238,181$222,184Accrued offering costs153,988153,988Promissory note100,000—Total current liabilities492,169376,172Non-current liabilitiesDeferred underwriting fee payable6,900,0006,900,000Total non-current liabilities6,900,0006,900,000Total Liabilities7,392,1697,276,172 Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.52 and$10.43 per share as of March 31, 2026, and December 31, 2025, respectively.242,020,416239,906,656 Shareholders’ DeficitPreference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as ofMarch 31, 2026 and December 31, 2025, respectively.——Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 10,717,143 shares issued andoutstanding, excluding 23,000,000 shares subject to redemption as of March 31, 2026 andDecember 31, 2025, respectively(1)1,0721,072Additional paid-in capital——Accumulated deficit(7,378,354)(7,265,053)Total Shareholders’ Deficit(7,377,282)(7,263,981)TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION ANDSHAREHOLDERS’ DEFICIT$242,035,303$239,918,847 (1)Includes 45,092 ordinary shares subject to cancellation and surrender as a result of Sponsor default on the share subscriptionreceivable. The ordinary shares are issued and outstanding as of March 31, 2026 andDecember 31, 2025 and are pendingcancellation and surrender. See note 8. The accompanying notes are an integral part of these unaudited financial statements. DRUGS MADE IN AMERICA ACQUISITION CORP.STATEMENTS OF OPERATIONS(UNAUDITED) (1)Includes 45,092 ordinary shares subject to cancellation and surrender provisions as a result of the Sponsor defaulting on the sharesubscription receivable. The ordinary shares are presented as issued and outstanding until such time th